What are the recommendations for addressing challenges in implementing asparaginase-based regimens in AYA patients with ALL?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
What are the recommendations for addressing challenges in implementing asparaginase-based regimens in AYA patients with ALL?
-
ナレーター：
-
著者：
The ALL Hub was pleased to speak with Ibrahim Aldoss, City of Hope, Duarte, US. We asked, What are the recommendations for addressing challenges in implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?
In this interview, Aldoss discusses the challenges associated with implementing asparaginase-based regimens in AYA patients with ALL and shares recommendations to overcome them, which were recently established and published by a US consensus panel.
This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.